© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
July 25, 2024
Article
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.